Internal medicine (Tokyo, Japan) · 2022
Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review.
Клинический случайСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hagiwara Yuya, Yamamoto Yoshiyuki, Inagaki Yuki, Tomisaki Reina, Tsuji Miki, Fukuda Soma, Fukuda Satoshi, Onoda Tsubasa, Suzuki Hirosumi, Niisato Yusuke, Tange Yoshitaka, Ikeda Naoya, Yamada Keiichi, Kobayashi Mariko, Akutsu Daisuke, Yamada Takeshi, Moriwaki Toshikazu, Narasaka Toshiaki, Suzuki Hideo, Tsuchiya Kiichiro
Аннотация
Dihydropyrimidine dehydrogenase (DPD) deficiency induces severe adverse events in patients receiving fluoropyrimidines. We encountered a 64-year-old DPD-deficient man with a severe capecitabine-related gastrointestinal disorder. He received capecitabine-containing chemotherapy after rectal cancer resection. During the first course of chemotherapy, he developed severe diarrhea, a fever, and hematochezia. Endoscopy revealed mucosal shedding with bleeding throughout the gastrointestinal tract. DPD deficiency was suspected because he developed many severe adverse events of capecitabine early and was finally confirmed based on the finding of a low DPD activity level in peripheral blood mononuclear cells. After one month of intensive care, hemostasis and mucosal healing were noted, although his gastrointestinal function did not improve, and he had persistent nutritional management issues.